Key Points
Ardelyx reported third-quarter product revenue of $125.5 million.
Full-year IBSRELA revenue guidance remains $350 million to $370 million.
Third-quarter net loss narrowed to $700,000.
On its third quarter of 2026 earnings call, held on Nov. 3, 2026, Ardelyx (NASDAQ:ARDX) reported total product revenue of $125.5 million. Expanding patient adoption and strategic clinical trials support the company's path toward commercial profitability in 2027. Three key takeaways from management's presentation stand out for long-term investors.
1. Phase 3 ACCEL Trial Reaches Full Enrollment Ahead of Schedule
Management completed patient enrollment early for its Phase 3 ACCEL clinical trial evaluating IBSRELA in chronic idiopathic constipation, or CIC, which is a long-term digestive condition with no known cause. Expanding into CIC offers access to a large patient population that shares symptoms with existing indications, creating a growth driver for the product line.
Our most advanced program with IBSRELA is our ACCEL Phase III clinical trial in patients with chronic idiopathic constipation or CIC. Today, we announced that we have fully enrolled the trial ahead of schedule.
-- Michael Raab, President and Chief Executive Officer
2. Field Support Expansion Targets Prior Authorization Friction
Healthcare providers face administrative friction when submitting prior authorizations, which are insurance approvals required before coverage begins. Management expanded its field reimbursement team to help medical offices navigate payer paperwork and convert prescriptions into completed fills.
In addition, we doubled our field reimbursement team to help HCPs navigate the prior authorization landscape.
-- Michael Raab, President and Chief Executive Officer
3. High Gross Margins Support Path to 2027 Profitability
Net loss narrowed to $700,000 in the third quarter while gross profit margins exceeded 95%. High gross margins combined with disciplined operating expenses, or opex, create financial leverage as revenue expands toward long-term targets.
Considering our greater than 95% gross profit margin and prudently managed opex, we anticipate our operating margin to grow as we move forward. That is the leverage of this business that I hope our shareholders appreciate.
-- Sue Hohenleitner, Chief Financial Officer
Looking Ahead
Commercial momentum continues across both commercial medicines, highlighting the strength of the business model. The company relies on gross margins above 95%, proprietary pharmacy distribution, and patent protection to support expansion. Leadership is watching gross-to-net realization, which measures revenue remaining after payer rebates.
Our focus is now to leverage that foundation and to build a pipeline to create long-term value.
-- Michael Raab, President and Chief Executive Officer
Focus remains fixed on achieving profitability in 2027 while advancing Phase 3 clinical assets.
We're a company with 2 first-in-class medicines, a solid financial foundation, a developing pipeline anchored by tenapanor and a team that has demonstrated that it can execute.
-- Michael Raab, President and Chief Executive Officer
The Motley Fool recommends Ardelyx. The Motley Fool has a disclosure policy.